News
GSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse events related to study drug in diabetes and 0 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results